SynOx Therapeutics’ Post

July is Sarcoma Awareness Month. Sarcoma is a group of cancers that begin in the bones and soft tissues. Tenosynovial giant cell tumor (TGCT) is a non-malignant, debilitating disease that also invades soft tissues and causes joint damage, swelling, pain, and reduced function. By sharing knowledge, resources and best practices we can make a difference for patients. Increased collaboration among medical professionals, researchers, patient advocacy groups and other stakeholders leads to better and earlier diagnoses, improved therapies, and better outcomes for those battling this rare disease. At SynOx we are dedicated to supporting this vision.    #SarcomaAwareness #RareDisease #TGCT

May is #BladderCancer Awareness Month 📣 And we are passionate about bringing you the latest news & updates 🎥 🗞️ "For final analysis [of AMBASSADOR] we see that adjuvant #pembrolizumab is very active, and it's a treatment option for our patients now with muscle invasive #urothelialcarcinoma in the adjuvant setting that are at high risk. So I think that these findings are very exciting and offering a new treatment option for our patients in this setting." 💡 Learn more from Andrea Apolo, MD, National Institutes of Health, Bethesda, MD 👉 https://lnkd.in/eFwV4Abt #VJOncology #BladderCancerAwarenessMonth

Did you know? July is Leiomyosarcoma Awareness Month, an opportunity to raise awareness about this rare but aggressive cancer that begins in smooth muscle tissue such as the uterus. There is currently no standardized screening for leiomyosarcoma; however, you should seek medical evaluation from a gynecologist if you are experiencing: -abnormal uterine bleeding -pelvic pain or pressure Patient advocate Linda Ryan shares a few questions you can ask your provider about this rare disease. You may also visit the link below to download our free fact sheet "Rare Tumor: Uterine Leiomyosarcoma" in English, Spanish, and Mandarin. https://bit.ly/3yhfxWf #LeiomyosarcomaAwareness #RareCancerAwareness

In rare diseases, accuracy is critical. As desmoid tumor awareness spreads with an FDA-approved drug, DTRF.org is a foundational resource. The goal is to empower and educate patients, caregivers, clinicians, and researchers with the latest in desmoid tumor science. On our website, under the menu heading "About Desmoid Tumors," are several pages designed to help anyone gain a solid understanding of this rare disease. Whether you're newly diagnosed or a veteran #DesmoidWarrior, please explore our website and share it with your physician and treatment team. 🔗 Visit DTRF.org #desmoidtumorawareness #DTRF #DesmoidTumorResearchFoundation #Desmoidian #DesmoidTumors #desmoidresearch #fibromatosis #aggressivefibromatosis #familialadenomatouspolyposis #OrphanDisease #raredisease

How precision medicine is tackling stubborn cancers in 2024 - Fast Company How precision medicine is tackling stubborn cancers in 2024  Fast Company Learn more https://lnkd.in/eDvPqnDT

🌟 Check out our top pick of the day! 🌟 📢 Groundbreaking Research Brings New Hope for Patients with Rare Abdominal Cancer Read more here: https://lnkd.in/dAAMW7fg 🔍 Stay informed with the best health insights and updates. Don't miss out! 🚀 #HealthNews #TopPick #medicalnews

Today, 19th April 2024, is #WorldLiverDay. Its motto is "Raising awareness about the vital role of the liver!". It emphasizes that liver diseases represent an enormous health burden worldwide. Unfortunately, not enough attention is paid to this problem; chronic liver diseases often worsen and go unrecognized, leading to complications including Hepatocellular Carcinoma (HCC). FUJIFILM Wako is committed to raising awareness of these diseases and offers opportunities for the early detection of liver fibrosis and Hepatocellular Carcinoma (HCC) using in vitro diagnostics. #FUJIFILM #Wako #Diagnostics #LiverDisease #LiverCancer

Delighted to share this work with co-authors from @mdandersoncancercenter and MUSC Hollings Cancer Center We looked at data from the Health Resources and Services Administration (HRSAgov), HHS data for #FQHCs and Centers for Disease Control and Prevention's BRFSS data for state estimates. The cross-sectional study includes 16 696 692 US adults served by approximately 1400 #FQHCs across the US. We found low breast, cervical, and colorectal cancer screenings. The contribution of the underscreened population served by FQHCs to the national underscreened general population was 16.9% for breast cancer, 29.7% for cervical cancer, and 14.7% for colorectal cancer screening. We conclude by highlighting the importance of examining practice-based data from the Health Resources and Services Administration (HRSAgov), HHS UDS for #FQHCs to generate insights into primary care settings that serve as safety nets for a significant proportion of the US population experiencing inequities! We call for appropriate resource allocations to improve cancer screening services for medically underserved populations in FQHCs and the need for systematic implementation efforts and #impsci to help address the unmet cancer screening needs in the US population.